"Cancer"

Christie Hospital, based in Manchester, is one of the top three cancer centres in Europe, with 2,500 staff, 300 volunteers and 30,000 members, treating over 44,000 patients each year

Generally speaking, mild gastritis, i.e. superficial gastritis, does not increase the risk of gastric cancer, but if not adjusted in time, it may further develop into atrophic gastritis, which is a state of "precancerous lesion".

The Dana-Farber Cancer Institute, founded in 1947, is a specialist cancer hospital affiliated with Harvard Medical School, a federally designated comprehensive cancer treatment centre in the United States, and has produced one Nobel Laureate in medicine.

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

Vocal cord cancer often leads to hoarseness, which is a common symptom of many diseases and can be easily overlooked by patients.

The Royal Marsden Hospital was founded in 1851 and was the first hospital in the world dedicated to cancer. The Royal Marsden Cancer Centre is the largest comprehensive cancer centre in Europe and is regarded as one of the top three cancer centres in the world, treating over 60,000 NHS and self-funded patients each year.

The clinical trial (PARABLE) will take place at 22 sites across the UK and is planned to recruit 192 patients at higher risk of developing heart problems. the PARABLE trial is led by researchers from the Royal Marsden Hospital, the University of Cambridge, and the Institute of Cancer Research (ICR) UK, and is managed by the Clinical Trials and Statistics Unit, funded by Cancer Research UK, at the Institute of Cancer Research (ICR). was conducted.

We all know that we need to pay attention to our diet after suffering from a disease, because improper diet will affect the recovery of the disease and the health of the patient.

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!

The FDA granted Fast Track designation to a new drug, IK-175, in combination with nabumab for the treatment of advanced uroepithelial carcinoma, after preliminary trial data showed encouraging and durable anti-tumor activity with a favorable safety profile.